
iRhythm Technologies (IRTC) Stock Forecast & Price Target
iRhythm Technologies (IRTC) Analyst Ratings
Bulls say
iRhythm Technologies has raised its 2025 revenue guidance to $735M-$740M, representing a robust 24.6% year-over-year growth at the midpoint, reflecting strong demand for its innovative cardiac monitoring solutions. The company achieved an adjusted gross margin of 71.1%, exceeding consensus estimates and demonstrating improved operational efficiency. Additionally, iRhythm is experiencing significant international expansion, with systems operational in Japan and ongoing growth in the UK private market, further underpinning its positive financial outlook.
Bears say
The financial outlook for iRhythm Technologies Inc. remains negative due to several identifiable risks, including a slowdown in growth to the low-teens and challenges in reaching profitability as indicated by the company's history of net losses. Furthermore, regulatory uncertainties stemming from a DOJ inquiry and FDA warning, combined with a highly competitive market and the potential for negative reimbursement developments, pose significant threats to its revenue prospects. Compounding these concerns are operational risks, including possible disruptions in sales execution and the necessity for restructuring in response to changes in the regulatory environment.
This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.
iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction
Start investing in iRhythm Technologies (IRTC)
Order type
Buy in
Order amount
Est. shares
0 shares